Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Angela Hawkes (NPI 1124206388)

Field	Value
Entity Type	Individual
Organization	Angela Hawkes
Address	2835 Horse Pen Creek Rd
City	Greensboro
State	NC
ZIP	27410
Taxonomy	Rheumatology Physician
NPI Enumerated	February 8, 2008

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

Provider billing is concentrated in biologic injectable and infusion services rather than routine office evaluation: the top revenue-driving entries are drug administration and biologic J-codes (J1602, J1745, J3262, J0717, J0129) alongside infusion/chemotherapy administration codes such as 96413. For example, 96413 generated $63.3K (2.8% of Medicare revenue) with 659 claims, indicating an active infusion capability in addition to drug dispensing. This code mix is consistent with a rheumatology practice that operates an infusion-focused service line.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 61.7% of the provider's Medicare revenue, with those codes individually reported as J1602 $631.5K (27.8%), J1745 $395.5K (17.4%), and J3262 $373.4K (16.4%). This dominance by three biologic drugs shows that a majority of the $2.3M Medicare revenue is driven by a narrow set of high-cost injectable therapies.

Payer mix is effectively single-payer at the claim level: lifetime Medicare revenue is $2.3M while there is no Medicaid billing on file. The absence of Medicaid activity means the provider’s revenue and operational profile, as reported here, are entirely Medicare-driven and may be sensitive to Medicare reimbursement or utilization changes.

Competitive standing on specific biologics is strong at the national level: J1602 ranks #21 of 1041 providers nationally (98th percentile; notably above typical national volume for this code) and J1745 ranks #29 of 1352 providers nationally (98th percentile; notably above typical national volume for this code). These two rankings indicate this provider is a major national-level participant for those specific infused biologic drugs, while other biologics show more typical volumes.

Statistical outlier patterns are mixed across codes: J1602 and J1745 are labeled "notably above typical national volume," marking them as high-volume outliers, whereas J3262 (ranks #113 of 618, 82th percentile) and J0717 (ranks #172 of 848, 80th percentile) are described as typical or unremarkable volume for their respective peer groups. Abatacept J0129 sits near the middle nationally (531 of 1221, 56th percentile) which suggests some diversification across biologic agents but concentrated strength in a subset of drugs.

The provider has long tenure in the Medicare program, with the NPI enumerated 2008-02-08 (~18 years ago), supporting an established referral base and the operational scale needed for high-volume infusion throughput. Longevity combined with the high national ranks on select biologics is consistent with an entrenched infusion practice rather than a newly established clinic.

Claim-level economics indicate per-mg unit billing driving volumes: J1602 shows 63.1K claims at $10 avg paid/claim ($631.5K revenue), J3262 shows 74.7K claims at $5 avg paid/claim ($373.4K revenue), and J0717 shows 90.8K claims at $4 avg paid/claim ($363.2K revenue). These very large claim counts paired with low average paid per claim are consistent with unit-based (1 mg) billing for biologic agents and explain why drug codes dominate revenue over evaluation codes.

Clinical evaluation visits comprise a small share of reported Medicare revenue relative to drug/infusion services: 99214 appears with 445 claims and $37.8K revenue (1.7% of Medicare revenue) and 99213 with 88 claims and $5.2K revenue (0.2%). This suggests the practice’s financial and operational emphasis is on administering biologic therapies and infusion services rather than office E/M revenue generation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

17 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1602	Injection, golimumab, 1 mg, for intravenous use	63,150	$10	$631.5K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	15,210	$30	$395.5K
J3262	Injection, tocilizumab, 1 mg	74,680	$10	$373.4K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	90,800	$1	$363.2K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	9,230	$30	$313.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	660	$100	$63.3K
J0897	Injection, denosumab, 1 mg	2,700	$20	$48.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	450	$90	$37.8K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	310	$50	$16.8K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	170	$50	$8K

Showing 1–10 of 17

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Angela Hawkes — 4 of 17 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

17 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	36	70	9,530	$30	$393.2K
J3262	11	40	37,160	$1	$224.8K
J0717	5	40	37,400	$1	$178.8K
J1602	1	70	11,900	$10	$175.9K
J1745	1	80	4,110	$30	$117.3K
J0897	167	430	2,100	$20	$63.9K
96413	10	280	90	$90	$15.8K
99214	1,928	18,060	110	$80	$15.1K
96401	13	80	120	$50	$9.5K
99215	4,083	5,720	40	$110	$7.7K

Showing 1–10 of 17

Related Providers

Other providers that share a Tax Identification Number (TIN) with Angela Hawkes, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
James Beekman	NC	Rheumatology Physician	$2.1M	$0
Eagle Physicians And Associates PA	NC	Ambulatory Surgical Clinic/Center	$337.9K	$2.4K
Chad Rund	NC	Anatomic Pathology & Clinical Pathology Physician	$319.6K	$0
Jason Hope	NC	Anatomic Pathology & Clinical Pathology Physician	$303K	$0
Huankai Hu	NC	Anatomic Pathology & Clinical Pathology Physician	$288.3K	$0
Dell Dembosky	NC	Anatomic Pathology Physician	$176.5K	$2.2K
Carl Szczesniak	NC	Anatomic Pathology & Clinical Pathology Physician	$156.3K	$1.6K
Courtney Freeman	NC	Nurse Practitioner	$101K	$0
Brian Miller	RI	Certified Registered Nurse Anesthetist	$34.6K	$0
Sarah Nowak	NC	Physician Assistant	$14.9K	$0

Nearby Providers

Other providers in the same ZIP code as Angela Hawkes, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lindley Habilitation Services Inc	NC	Community/Behavioral Health Agency	$0	$187.9M
Quest Diagnostics Clinical Laboratories Inc	NC	Clinical Medical Laboratory	$14.6M	$22M
Health & Home Services, Inc.	NC	Nursing Care Agency	$0	$23.9M
Exceptional Family Support, LLC	NC	Community/Behavioral Health Agency	$0	$14.4M
Solstas Lab Partners Group LLC	NC	Clinical Medical Laboratory	$0	$11.7M
Asap Labs And Care, LLC	NC	Clinical Medical Laboratory	$78.4K	$1.7M
Greensboro Ophthalmology Asc LLC	NC	Ambulatory Surgical Clinic/Center	$750.1K	$379.4K
Paula Pecen	NC	Ophthalmology Physician	$1.1M	$0
Mario Mitkov	NC	Dermatology Physician	$881.9K	$0
Keshavpal Reddy	NC	Psychiatry Physician	$146.2K	$617K

Angela Hawkes — Billing Profile & Reimbursement Data

Sign up for Angela Hawkes — Billing Profile & Reimbursement Data policy alerts

Angela Hawkes — Billing Profile & Reimbursement Data

Sign up for Angela Hawkes — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References